(2018) An Overview of FGF19 and FGF21: The Therapeutic Role in the Treatment of the Metabolic Disorders and Obesity. Hormone and Metabolic Research. pp. 441-452. ISSN 0018-5043
Full text not available from this repository.
Abstract
Fibroblast growth factors (FGFs) are responsible for the regulation of a wide range of biological functions, among which cellular proliferation, survival, migration, and differentiation could be pointed out. FGF19 controls the enterohepatic bile acid/cholesterol system, and FGF21 modulates fatty acid/glucose metabolism. Obesity, type 2 diabetes, coronary artery disease, and cancer, all can alter FGF21 circulating concentrations. In contrast to FGF21, metabolic diseases exhibit reduced serum FGF19 levels. Accordingly, FGF19 and FGF21 play important roles in regulating glucose and lipid metabolism. Hence, we present here a timely review on the relationship between FGF19/21 and metabolic diseases, especially obesity, and their probable role in development and treatment of obesity seems necessary.
Item Type: | Article |
---|---|
Keywords: | fgf21 fgf19 metabolic disorders obesity fibroblast-growth-factor increases energy-expenditure improves insulin sensitivity activated-receptor-gamma hepatic lipid-metabolism bile-acid biosynthesis brown adipose-tissue weight-loss ppar-alpha serum concentrations |
Subjects: | WH Hemic and Lymphatic Systems > WH 600-700 Lymphatic System |
Divisions: | Faculty of Medicine > Departments of Clinical Sciences > Department of Neurology Food Security Research Center |
Page Range: | pp. 441-452 |
Journal or Publication Title: | Hormone and Metabolic Research |
Journal Index: | ISI |
Volume: | 50 |
Number: | 6 |
Identification Number: | https://doi.org/10.1055/a-0623-2909 |
ISSN: | 0018-5043 |
Depositing User: | Zahra Otroj |
URI: | http://eprints.mui.ac.ir/id/eprint/6489 |
Actions (login required)
View Item |